Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Vishal K. Singh, Ritika Srivastava, Parth Sarthi Sen Gupta, Farha Naaz, Himani Chaurasia, Richa Mishra, Malay Kumar Rana & Ramendra K. Singh. (2021) Anti-HIV potential of diarylpyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors: design, synthesis, docking, TOPKAT analysis and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics 39:7, pages 2430-2446.
Read now
Read now
Yuqing Gong, Pallabita Chowdhury, Prashanth K.B. Nagesh, Theodore J. Cory, Chelsea Dezfuli, Sunitha Kodidela, Ajay Singh, Murali M. Yallapu & Santosh Kumar. (2019) Nanotechnology approaches for delivery of cytochrome P450 substrates in HIV
treatment. Expert Opinion on Drug Delivery 16:8, pages 869-882.
Read now
Read now
Articles from other publishers (5)
Kiran S. Toti, Nicole Pribut, Michael D’Erasmo, Madhuri Dasari, Savita K. Sharma, Perry W. Bartsch, Samantha L. Burton, Hannah B. Gold, Anatoliy Bushnev, Cynthia A. Derdeyn, Adriaan E. Basson, Dennis C. Liotta & Eric J. Miller. (2023) Expanding the toolbox of metabolically stable lipid prodrug strategies. Frontiers in Pharmacology 13.
Crossref
Crossref
Saiful Islam, Theodosia Teo, Malika Kumarasiri, Martin Slater, Jennifer H. Martin, Shudong Wang & Richard Head. (2022) Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells. Pharmaceuticals 15:10, pages 1186.
Crossref
Crossref
Boshi Huang, Wenmin Chen, Tong Zhao, Zhenyu Li, Xiangyi Jiang, Tiziana Ginex, David Vílchez, Francisco Javier Luque, Dongwei Kang, Ping Gao, Jian Zhang, Ye Tian, Dirk Daelemans, Erik De Clercq, Christophe Pannecouque, Peng Zhan & Xinyong Liu. (2019) Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles. Journal of Medicinal Chemistry 62:4, pages 2083-2098.
Crossref
Crossref
Na Liu, Lei Wei, Li Huang, Fei Yu, Weifan Zheng, Bingjie Qin, Dong-Qin Zhu, Susan L. Morris-Natschke, Shibo Jiang, Chin-Ho Chen, Kuo-Hsiung Lee & Lan Xie. (2016) Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus. Journal of Medicinal Chemistry 59:8, pages 3689-3704.
Crossref
Crossref
Hong-Tao Xu, Susan P. Colby-Germinario, Maureen Oliveira, Yingshan Han, Yudong Quan, Veronica Zanichelli & Mark A. Wainberg. (2014) The Connection Domain Mutation N348I in HIV-1 Reverse Transcriptase Enhances Resistance to Etravirine and Rilpivirine but Restricts the Emergence of the E138K Resistance Mutation by Diminishing Viral Replication Capacity. Journal of Virology 88:3, pages 1536-1547.
Crossref
Crossref